Just a moment, the page is loading...

GSK-MY1047/BRL-029060/1/CPMS-120




A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.
paroxetine
MY1047/BRL-029060/1/CPMS-120
Panic Disorder
Phase 3
An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
December 2014